{"id":"NCT01323192","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder","officialTitle":"A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2011-03-25","resultsPosted":"2013-09-06","lastUpdate":"2013-09-06"},"enrollment":284,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention-Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"JNS001","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"JNS001","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.","primaryOutcome":{"measure":"Change From Baseline to Endpoint in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Total Attention Deficit-Hyperactivity Disorder (ADHD) Symptoms Scores of Conners' Adult ADHD Rating Scale - Observer Screening Version (CAARS-O: SV)","timeFrame":"Baseline (Day 0) to Endpoint (Week 8)","effectByArm":[{"arm":"JNS001","deltaMin":-12.5,"sd":9.27},{"arm":"Placebo","deltaMin":-7.9,"sd":9.61}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":30,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":143},"commonTop":["Decreased appetite","Nasopharyngitis","Insomnia","Palpitations","Thirst"]}}